This multitherapy is based on the administration of a low dose of cyclophosphamide, which is a combination of melatonin, somatostatin, bromocriptine, retinoids, and the adrenocorticotropic hormone, to improve the drug efficacy on tumour cells and the patients’ quality of life [43]. Here, POMC is linked to neoplasm.